Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells. Eliminating the T cells from the donor cells before transplanting them may prevent this from happening. Infusions of donor lymphocytes may decrease the body's rejection of the transplanted peripheral stem cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic stem cell transplantation followed by donor lymphocyte infusions in treating patients who have hematologic cancer.

Study summary:

OBJECTIVES: - Determine the effect of irradiated donor T-cell infusion on donor T-cell chimerism 6 weeks after hematopoietic stem cell transplantation in patients with hematologic malignancies. - Determine the infusional toxic effects of irradiated donor lymphocytes in these patients. - Determine the risk of acute and chronic graft-versus-host disease from donor lymphocyte infusions on day 45 and day 100 posttransplantation in HLA 6/6 matched transplantations from a related donor in these patients. - Determine disease-free survival, cytomegalovirus reactivation, and relapse in patients treated with this regimen. - Determine transplant-related mortality and death from all causes in patients treated with this regimen. OUTLINE: - Preparative regimen: Patients receive fludarabine IV over 30 minutes on days -8 to -4 and cyclophosphamide IV over 1 hour on days -3 and -2. Patients undergo total body irradiation on days -7 to -4. - Pretransplantation irradiated donor lymphocyte infusion (DLI): Patients receive irradiated DLI on day -4. - Hematopoietic stem cell transplantation (HSCT): Patients undergo allogeneic HSCT on day 0. - Graft-versus-host disease prophylaxis: Patients receive oral cyclosporine on days 44-120. - Posttransplantation DLI: Patients receive DLI on days 45 and 100. Patients with chronic myelogenous leukemia in chronic phase who are polymerase chain reaction negative for bcr/abl receive DLI on day 45 only. Patients are followed at 3, 6, and 12 months and then annually thereafter. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of any of the following hematologic malignancies: - Chronic myelogenous leukemia (CML) in chronic phase meeting 1 of the following criteria: - Under 41 years of age with no prior imatinib mesylate therapy - 10 to 55 years of age and failed prior imatinib mesylate therapy - 41 to 55 years of age for whom imatinib mesylate is not the treatment of choice - CML in accelerated phase or blast transformation - Acute lymphoblastic leukemia meeting any of the following criteria: - Over 18 years of age and in first remission with high-risk features (e.g., WBC greater than 100,000/mm^3, karyotypes t[9;22], t[4], t[19], t[11], and biphenotypic leukemia) - Second or subsequent remission - Primary induction failure - Partially responding or untreated relapse - Acute myeloid leukemia meeting any of the following criteria: - First remission, except with good-risk karyotypes (e.g., M3 t[15;17], M4E0 inv[16], t[8;21]) - Second or subsequent remission - Primary induction failure - Resistant relapse - Myelodysplastic syndromes of any of the following types: - Refractory anemia (RA) with transfusion dependence - RA with excess blasts - In transformation to acute leukemia - Chronic myelomonocytic leukemia - Myeloproliferative disorders in transformation to acute leukemia, of any of the following types: - Myelofibrosis - Polycythemia vera - Essential thrombocythemia - Chronic lymphocytic leukemia that is refractory to fludarabine with 1 of the following: - Bulky progressive disease - Thrombocytopenia (WBC no greater than 100,000/mm^3)* - Anemia (hemoglobin no greater than 10 g/dL)* NOTE: *Not due to recent chemotherapy - Non-Hodgkin's lymphoma, including mantle cell lymphoma, relapsing or refractory to current chemotherapy and monoclonal antibody therapy and unsuitable for autologous stem cell transplantation - Availability of a HLA-identical (6/6) family donor PATIENT CHARACTERISTICS: Age - 10 to 55 Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - See Disease Characteristics Hepatic - Bilirubin no greater than 4 mg/dL - Transaminases no greater than 3 times upper limit of normal Renal - Creatinine no greater than 3 mg/dL Cardiovascular - LVEF at least 40% of predicted Pulmonary - DLCO at least 60% of predicted Other - Not pregnant - Negative pregnancy test - HIV negative - No severe psychiatric illness or mental deficiency that would preclude giving informed consent or complying with study treatment - No major illness or organ dysfunction that would preclude transplantation - No other prior malignancy except basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics Chemotherapy - See Disease Characteristics - No prior continuous busulfan for more than 6 months duration Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified



Primary Contact:

Study Chair
Austin J. Barrett, MD, FRCP
NHLBI - Bone Marrow Transplantation Unit

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: December 12, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.